Navigation Links
Free-radical busting antioxidants might not promote healthy hearts

Antioxidants, such as beta-carotene and Vitamin E, have been touted for their ability to protect against heart disease. This protective effect is attributed to their ability to prevent the oxidation of bad cholesterol by free radicals—a process thought to contribute to the build-up of disease-causing fatty deposits on artery walls. But a new study, published online on April 10 in The Journal of Experimental Medicine, suggests that the heart-healthy effect of one antioxidant has little to do with cholesterol oxidation.

A group of researchers at the University of New South Wales in Australia, led by Roland Stocker, studied a cholesterol-lowering drug called Probucol (Lorelco) in laboratory rodents with vascular disease. Probucol reduces the risk of heart disease in humans, but is no longer prescribed in the US and Australia because of adverse side effects: a tendency to lower good cholesterol along with the bad and the potential to induce an irregular heartbeat. Probucol is still available in Canada and Europe.

In their new study, Stocker and his colleagues show that the protective effect of probucol has nothing to do with its ability to scavenge oxygen free radicals, as the free radical-busting part of the drug alone was ineffective in protecting animals against heart disease. Instead, a different part of the probucol molecule was doing the beneficial work.

In fact, contrary to widely accepted opinion, the group found no relationship between the levels of oxidized cholesterol in blood vessels and the severity of heart disease. This might help explain the disappointing results of clinical trials with other free radical-scavenging antioxidants, such as Vitamin E, which have shown no protective effect against heart disease in humans.

The protective effect of these compounds depended on the induction of a cellular enzyme called heme oxygenase-1 (HO-1). HO-1 is known to protect against atherosclerosis in animal models, although the mechanism is not completely clear. Not surprisingly, HO-1 was not induced by Vitamin E.

Drugs closely related to probucol that contain the protective part of the drug were just as protective as the original drug. If these probucol relatives—one of which is now being tested in humans—are free of side effects, they may provide a more effective alternative to current therapies.


'"/>

Source:Journal of Experimental Medicine


Related biology news :

1. York researchers develop pollution-busting plants to clean up contaminated land
2. Clot-busting drug helps revive cardiac arrest patients
3. Red delicious, Northern Spy apples have most antioxidants, chemists find
4. Unique tomatoes tops in disease-fighting antioxidants
5. Honeydew honeys are better antioxidants than nectar honeys
6. Pistachios lower cholesterol, provide antioxidants
7. Antibiotic might fight HIV-induced neurological problems
8. Newly discovered pathway might help in design of cancer drugs
9. Compound might defeat African sleeping sickness, clinical trial beginning this month
10. Stem cells electric abilities might help their safe clinical use
11. Software might revolutionize glucose monitoring in critically ill patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based and ... 2022", published by MarketsandMarkets, the market is expected to be worth USD 18.98 ... Continue Reading ... ...      ...
(Date:3/22/2017)... VILNIUS, Lithuania , March 21, 2017 /PRNewswire/ ... identification and object recognition technologies, today announced the ... development kit (SDK), which provides improved facial recognition ... safety cameras on a single computer. The new ... algorithms to improve accuracy, and it utilizes a ...
(Date:3/22/2017)... , March 21, 2017 Vigilant ... company serving law enforcement agencies, announced today the appointment ... as director of public safety business development. ... law enforcement experience, including a focus on the aviation ... his most recent position, Mr. Sheridan served as the ...
Breaking Biology News(10 mins):
(Date:4/27/2017)... ... ... Mitotech S.A, a Luxembourg based clinical stage biotechnology company, announced positive results of ... devastating genetic disease that leads to a sudden and rapid loss of central vision. ... 11778, 14484 and 3460 mutations and having experienced the onset of symptoms more than ...
(Date:4/27/2017)... Yorba Linda, Ca (PRWEB) , ... April 27, ... ... will hear from a practicing internist, who will review how testing for 1,25-Dihydroxyvitamin ... signs that prompt ordering of 25-OH-vitamin D and 1,25 dihydroxyvitamin D. , Dr. ...
(Date:4/27/2017)... ... April 27, 2017 , ... Volunteers supported by ... engineers, and industry professionals in visiting U.S. Congressional offices in Washington, D.C., yesterday ... world photonics industry. , This year, National Photonics Initiative (NPI) Congressional ...
(Date:4/27/2017)... 27, 2017  Kinexum, a distinguished resource for research, ... the appointment of Thomas C. Seoh as ... M.D., Kinexum founder, who becomes Executive Chairman and will ... clients. Thomas Seoh commented, "I ... mission and lead the firm,s remarkable team of life ...
Breaking Biology Technology: